Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

Change Text Size:

BRIEF-SQZ Biotechnologies Receives FDA Fast Track Designation For Its Lead Cell Therapy Candidate For The Treatment Of HPV16+ Tumors

BY Reuters
— 5:54 PM ET 04/27/2022

April 27 (Reuters) - SQZ Biotechnologies Co (SQZ):

* SQZ BIOTECHNOLOGIES RECEIVES FDA FAST TRACK DESIGNATION FOR ITS LEAD CELL THERAPY CANDIDATE FOR THE TREATMENT OF HPV16+ TUMORS Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More SQZ News

SQZ Biotechnologies Receives FDA Fast Track Designation for SQZ-PBMC-HPV for the Treatment of HPV16+ Tumors
Benzinga - 5:19 PM ET 04/27/2022
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
Business Wire - 4:45 PM ET 04/27/2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga - 2:41 PM ET 04/27/2022